C(OC(=O)[NH:7][C:8]1[CH:13]=[CH:12][C:11]([N:14]2[CH:18]=[CH:17][CH:16]=[CH:15]2)=[CH:10][C:9]=1[NH2:19])(C)(C)C.[CH2:21]([O:23][C:24]([C:26]1[N:27]=[CH:28][O:29][C:30]=1[C:31]1[CH:36]=[CH:35][CH:34]=[C:33]([C:37]2OC(C)(C)O[C:41](=[O:43])[CH:42]=2)[CH:32]=1)=[O:25])[CH3:22].C(O)(C(F)(F)F)=O>C(Cl)Cl>[CH2:21]([O:23][C:24]([C:26]1[N:27]=[CH:28][O:29][C:30]=1[C:31]1[CH:36]=[CH:35][CH:34]=[C:33]([C:37]2[CH2:42][C:41](=[O:43])[NH:19][C:9]3[CH:10]=[C:11]([N:14]4[CH:18]=[CH:17][CH:16]=[CH:15]4)[CH:12]=[CH:13][C:8]=3[N:7]=2)[CH:32]=1)=[O:25])[CH3:22]The title compound was prepared from (2-amino-4-pyrrol-1-yl-phenyl)-carbamic acid tert.-butyl ester (Example J2) (164 mg) and 5-[3-(2,2-dimethyl-6-oxo-6H-[1,3]dioxin-4-yl)-phenyl]-oxazole-4-carboxylic acid ethyl ester (Example L6) (206 mg) according to the general procedure M. The obtained material was deprotected and cyclized by treatment with TFA in CH2Cl2 according to the general procedure N. Obtained as a light yellow solid (63 mg).
Loading…